Nanobiotix SA

NANO

Company Profile

  • Business description

    Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.

  • Contact

    60 Rue de Wattignies
    Paris75012
    FRA

    T: +33 140260470

    https://www.nanobiotix.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    103

Stocks News & Analysis

stocks

Eli Lilly receives FDA approval to add another oral GLP-1 to market

Wide moat Eli Lilly receives FDA approval for obesity pill.
stocks

Our top ASX picks in every sector

These companies are our favourite choices for investors wanting to boost Aussie equity exposure.
stocks

Which of the 3 giant AI IPOs should you buy?

OpenAI, Anthropic, and Databricks are expected to go public this year at massive valuations.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,774.90124.80-1.40%
CAC 407,962.390.000.00%
DAX 4023,168.08130.81-0.56%
Dow JONES (US)46,504.6761.07-0.13%
FTSE 10010,436.2971.500.69%
HKSE25,116.53177.50-0.70%
NASDAQ21,879.1838.230.18%
Nikkei 22553,123.49660.221.26%
NZX 50 Index12,902.1576.280.59%
S&P 5006,582.697.370.11%
S&P/ASX 2008,579.50105.50-1.21%
SSE Composite Index3,919.2929.27-0.74%

Market Movers